First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value
Crossref DOI link: https://doi.org/10.1007/s00408-016-9912-1
Published Online: 2016-07-04
Published Print: 2016-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wuyts, Wim A.
Kolb, Martin
Stowasser, Susanne
Stansen, Wibke
Huggins, John T.
Raghu, Ganesh
Funding for this research was provided by:
Boehringer Ingelheim
License valid from 2016-07-04